Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + GDC-0853
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rosuvastatin + GDC-0853 is a combination of two pharmaceutical agents. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and triglycerides in the blood, reduce the risk of heart attack and stroke, and treat familial hypercholesterolemia by inhibiting cholesterol synthesis in the liver[1][2][8]. GDC-0853 (also known as fenebrutinib) is a small molecule Bruton’s tyrosine kinase (BTK) inhibitor developed for autoimmune diseases such as systemic lupus erythematosus (SLE)[5]. The combination has been studied in drug-drug interaction trials to assess potential pharmacokinetic interactions between these agents[3][4].
- Brand names
- CrestorEzallor Sprinkle
- Other names
- rosuvastatin calciumfenebrutinib
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on rosuvastatin + GDC-0853.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + GDC-0853.